SCHEMBL23488176

SCHEMBL23488176

COc1ccc(COc2c(Cl)cc(C(=O)O[C@H]3[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]3O)cc2OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 5/20 0.44
LGALS8 O00214 3/20 0.43
SLC5A1 P13866 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
LGALS3 P17931 2/20 0.41
LGALS4 P56470 1/20 0.41
LGALS9 O00182 1/20 0.40
LGALS1 P09382 1/20 0.40
LGALS7; LGALS7B P47929 1/20 0.40
TNFRSF1A P19438 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488707 0.92 LGALS8 (0.47) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL23488610 0.92 LGALS8 (0.47) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL23488633 0.91 LGALS3 (0.46) SLC5A2LGALS8LGALS3LGALS4LGALS9
SCHEMBL23488764 0.88 SNCA (0.44) LGALS8LGALS3LGALS4TNFRSF1ACA2
SCHEMBL23488445 0.87 LGALS3 (0.40) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL23488542 0.86 LGALS3 (0.38) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL23488588 0.86 LGALS3 (0.40) SLC5A2LGALS8LGALS3LGALS4LGALS9
SCHEMBL23488701 0.86 LGALS8 (0.50) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL23488628 0.85 LGALS8 (0.49) SLC5A2LGALS8LGALS3LGALS4LGALS9
SCHEMBL23488294 0.85 LGALS8 (0.55) LGALS8LGALS3LGALS4LGALS9LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 SLC5A2 10/4885LGALS8 61/4885SLC5A1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.